Barclays Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Barclays analyst Luke Sergott upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $310 to $400.
Barclays analyst Luke Sergott upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $310 to $400.